Outcomes after Plerixafor Plus FLAG-IDA (PLERIFLAG) Versus FLAG-IDA +/- Gentuzumab for Adult Patients with First Relapsed/Refractory AML: A Propensity Score Analysis from the Pethema Registry Juan Miguel M. Bergua Burgues , Isabel Cano-Ferri , Cano Ferri , David Martinez-Cuadron , Blanca Boluda , Pilar Martinez-Sanchez , Rebeca Rodriguez-Veiga , Jordi Esteve , Susana Vives , Josefina Serrano , Maria-Belen Vidriales , Olga Salamero , Carlos Carretero , Ana Jimenez-Ubieto , Ignacio Casas , Rocio Cardesa , Marina Diaz-Beya , Salut Brunet , Celina Benavente , Jose Antonio Perez-Simon , Federico Moscardo , Eliana Aguiar , Manuel Perez Encinas , Aurelio Lopez Martinez , Carlos Rguez , A. Cabello , Jorge Labrador , Lissette Del Pilar Costilla , Claudia Sossa , Teresa Bernal Del Castillo , Miguel A. Sanz , Pau Montesinos Blood（2019）
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
